AGL 24.40 Increased By ▲ 1.46 (6.36%)
AIRLINK 109.29 Decreased By ▼ -2.00 (-1.8%)
BOP 5.29 Increased By ▲ 0.04 (0.76%)
CNERGY 3.67 Decreased By ▼ -0.05 (-1.34%)
DCL 8.00 Increased By ▲ 0.01 (0.13%)
DFML 44.30 Increased By ▲ 4.03 (10.01%)
DGKC 88.80 Increased By ▲ 0.80 (0.91%)
FCCL 21.99 No Change ▼ 0.00 (0%)
FFBL 42.28 Increased By ▲ 0.08 (0.19%)
FFL 8.90 Increased By ▲ 0.35 (4.09%)
HUBC 151.70 Decreased By ▼ -1.59 (-1.04%)
HUMNL 10.35 Decreased By ▼ -0.10 (-0.96%)
KEL 4.45 Decreased By ▼ -0.05 (-1.11%)
KOSM 3.95 Increased By ▲ 0.10 (2.6%)
MLCF 36.60 Decreased By ▼ -0.20 (-0.54%)
NBP 49.16 Increased By ▲ 1.17 (2.44%)
OGDC 131.70 Decreased By ▼ -0.10 (-0.08%)
PAEL 26.31 Increased By ▲ 0.16 (0.61%)
PIBTL 6.07 Increased By ▲ 0.04 (0.66%)
PPL 115.45 Decreased By ▼ -0.05 (-0.04%)
PRL 22.67 Increased By ▲ 0.07 (0.31%)
PTC 12.50 Decreased By ▼ -0.08 (-0.64%)
SEARL 56.19 Increased By ▲ 0.50 (0.9%)
TELE 7.40 Increased By ▲ 0.20 (2.78%)
TOMCL 37.69 Increased By ▲ 0.69 (1.86%)
TPLP 8.34 Increased By ▲ 0.49 (6.24%)
TREET 15.33 Increased By ▲ 0.03 (0.2%)
TRG 59.96 Increased By ▲ 5.41 (9.92%)
UNITY 32.34 Increased By ▲ 0.48 (1.51%)
WTL 1.18 Increased By ▲ 0.01 (0.85%)
BR100 8,406 Increased By 61.8 (0.74%)
BR30 26,453 Increased By 106 (0.4%)
KSE100 79,397 Increased By 409.9 (0.52%)
KSE30 25,518 Increased By 153.1 (0.6%)
Business & Finance

Roche joins AstraZeneca in ditching US bladder cancer indication for immunotherapies

  • Tecentriq initially won accelerated FDA approval in 2016 for people previously treated for the most common form of bladder cancer, but was required to gather follow-up data in order to win regular approval.
Published March 8, 2021

ZURICH: Roche on Monday joined AstraZeneca in withdrawing cancer immunotherapies from US use for bladder cancer that has already been treated with platinum-based chemotherapy, after follow-up studies failed to meet goals.

Basel-based Roche said in a statement it was withdrawing the US indication for Tecentriq, with some $3 billion in 2020 sales, in prior-platinum treated metastatic urothelial carcinoma.

In February, AstraZeneca announced a similar move for its $2 billion-per-year drug Imfinzi.

Both Tecentriq and Imfinzi aim to take the brakes off the immune system by binding with a protein called PD-L1, or programmed death-ligand 1, expressed on tumor cells and which is seen in helping prevent the immune system from recognising it as cancer.

After so-called accelerated US Food and Drug Administration (FDA) approval for bladder cancer, however, the drugs failed to deliver positive follow-up data required by regulators, prompting discussions that led to the medicines being dropped in this indication.

Other treatment areas for Tecentriq and Imfinzi are not impacted by the companies' separate moves.

"This decision was made in consultation with the US Food and Drug Administration as part of an industry-wide review of accelerated approvals with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals," Roche said.

Tecentriq initially won accelerated FDA approval in 2016 for people previously treated for the most common form of bladder cancer, but was required to gather follow-up data in order to win regular approval.

Doubts emerged quickly, however, as Roche said in 2017 Tecentriq failed to show a survival benefit in second-line bladder cancer, raising questions over whether the FDA should reverse the accelerated approval.

Tecentriq's other approved indications include non-small cell lung cancer, small cell lung cancer, certain types of bladder cancer, a kind of triple negative breast cancer and for liver cancer.

Comments

Comments are closed.